المؤلفون: Kinzer, Jill L., Halseth, Troy A., Kang, Jukyung, Kim, Sang Yeop, Kumaran, Preethi, Ford, Michael, Saveliev, Sergei, Skilton, St John, Schwendeman, Anna

المصدر: International Journal of Pharmaceutics ; volume 635, page 122646 ; ISSN 0378-5173

مصطلحات موضوعية: Pharmaceutical Science

الإتاحة: https://doi.org/10.1016/j.ijpharm.2023.122646Test
https://api.elsevier.com/content/article/PII:S0378517323000662?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0378517323000662?httpAccept=text/plainTest

المؤلفون: Yeop Kim, Sang, Kang, Jukyung, V Fawaz, Maria, Yu, Minzhi, Xia, Ziyun, E Morin, Emily, Mei, Ling, Olsen, Karl, Li, Xiang-An, Schwendeman, Anna

العلاقة: https://dx.doi.org/10.25402/nnm.24973149Test; https://dx.doi.org/10.2217/nnm-2023-0222Test

الإتاحة: https://doi.org/10.25402/nnm.24973149.v110.25402/nnm.2497314910.2217/nnm-2023-0222Test
https://tandf.figshare.com/articles/dataset/Phospholipids_impact_the_protective_effects_of_HDL-mimetic_nanodiscs_against_lipopolysaccharide-induced_inflammation_-_supplementary_dataset/24973149/1Test

المؤلفون: Kim, Sang Yeop, Kang, Jukyung, Fawaz, Maria V, Yu, Minzhi, Xia, Ziyun, Morin, Emily E, Mei, Ling, Olsen, Karl, Li, Xiang-An, Schwendeman, Anna

المصدر: Nanomedicine; Dec2023, Vol. 18 Issue 29, p2127-2142, 16p

المؤلفون: Patel, Hiren, Ding, Bei, Ernst, Kelsey, Shen, Lei, Yuan, Wenmin, Tang, Jie, Drake, Lindsey, Kang, Jukyung, Li, Yaoxin, Chen, Zhan, Schwendeman, Anna

المصدر: International Journal of Nanomedicine ; volume Volume 14, page 3069-3086 ; ISSN 1178-2013

الإتاحة: https://doi.org/10.2147/ijn.s179837Test
https://www.dovepress.com/getfile.php?fileID=49447Test

المؤلفون: Pisupati, Karthik, Benet, Alexander, Tian, Yuwei, Okbazghi, Solomon, Kang, Jukyung, Ford, Michael, Saveliev, Sergei, Sen, K. Ilker, Carlson, Eric, Tolbert, Thomas J., Ruotolo, Brandon T., Schwendeman, Steven P., Schwendeman, Anna

المصدر: mAbs ; volume 9, issue 7, page 1197-1209 ; ISSN 1942-0862 1942-0870

الإتاحة: https://doi.org/10.1080/19420862.2017.1347741Test

المؤلفون: Li, Tinghui, Chandrashekar, Aishwarya, Beig, Avital, Walker, Jennifer, Hong, Justin K.Y., Benet, Alexander, Kang, Jukyung, Ackermann, Rose, Wang, Yan, Qin, Bin, Schwendeman, Anna S., Schwendeman, Steven P.

المساهمون: U.S. Food and Drug Administration

المصدر: European Journal of Pharmaceutics and Biopharmaceutics ; volume 158, page 401-409 ; ISSN 0939-6411

الإتاحة: https://doi.org/10.1016/j.ejpb.2020.10.008Test
https://api.elsevier.com/content/article/PII:S0939641120303088?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0939641120303088?httpAccept=text/plainTest

المؤلفون: Vallejo, Daniel D., Kang, Jukyung, Coghlan, Jill, Ramírez, Carolina Rojas, Polasky, Daniel A., Kurulugama, Ruwan T., Fjeldsted, John C., Schwendeman, Anna A., Ruotolo, Brandon T.

المساهمون: Agilent Technologies

المصدر: Analytical Chemistry ; volume 93, issue 48, page 16166-16174 ; ISSN 0003-2700 1520-6882

الإتاحة: https://doi.org/10.1021/acs.analchem.1c03946Test

المؤلفون: Kim, Sang Yeop, Yu, Minzhi, Morin, Emily E., Kang, Jukyung, Kaplan, Mariana J., Schwendeman, Anna

مصطلحات موضوعية: Rheumatology, Health Sciences

وصف الملف: application/pdf

العلاقة: Kim, Sang Yeop; Yu, Minzhi; Morin, Emily E.; Kang, Jukyung; Kaplan, Mariana J.; Schwendeman, Anna (2020). "High‐Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy." Arthritis & Rheumatology 72(1): 20-30.; https://hdl.handle.net/2027.42/152788Test; Arthritis & Rheumatology; Shoenfeld Y, Szyper‐Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, et al. Autoantibodies against protective molecules—C1q, C‐reactive protein, serum amyloid P, mannose‐binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 227 – 39.; Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1‐specific self‐antibodies in cardiovascular disease. Lab Invest 2016; 96: 708 – 18.; Delgado Alves J, Kumar S, Isenberg DA. Cross‐reactivity between anti‐cardiolipin, anti‐high‐density lipoprotein and anti‐apolipoprotein A‐I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003; 42: 893 – 9.; Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high‐density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 137 – 46.; Yu HH, Chen PC, Yang YH, Wang LC, Lee JH, Lin YT, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population‐based cohort study. Atherosclerosis 2015; 243: 11 – 8.; Castejon R, Castañeda A, Sollet A, Mellor‐Pita S, Tutor‐Ureta P, Jimenez‐Ortiz C, et al. Short‐term atorvastatin therapy improves arterial stiffness of middle‐aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus 2017; 26: 355 – 64.; Orekhov AN, Misharin AY, Tertov VV, Khashimov K, Pokrovsky SN, Repin VS, et al. Artificial HDL as an anti‐atherosclerotic drug. Lancet 1984; 2: 1149 – 50.; Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol 2013; 24: 480 – 6.; Tardif JC, Grégoire J, L’Allier PL, Ibrahim R, Lespérance J, Heinonen TM, et al. Effects of reconstituted high‐density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675 – 82.; Tricoci P, D’Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, et al. Infusion of reconstituted high‐density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial. J Am Heart Assoc 2015; 4: e002171.; CSL Behring, sponsor. Study to investigate CSL112 in subjects with acute coronary syndrome (AEGIS‐II). Clinicaltrails.gov identifier: NCT03473223; 2018.; Morin EE, Guo L, Schwendeman A, Li XA. HDL in sepsis: risk factor and therapeutic approach. Front Pharmacol 2015; 6: 244.; Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high‐density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601 – 8.; Zhang Z, Datta G, Zhang Y, Miller AP, Mochon P, Chen YF, et al. Apolipoprotein A‐I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 2009; 297: H866 – 73.; Moreira RS, Irigoyen M, Sanches TR, Volpini RA, Camara NO, Malheiros DM, et al. Apolipoprotein A‐I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis. Am J Physiol Regul Integr Comp Physiol 2014; 307: R514 – 24.; Charles‐Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, et al. Treatment with an apolipoprotein A‐1 mimetic peptide in combination with pravastatin inhibits collagen‐induced arthritis. Clin Immunol 2008; 127: 234 – 44.; Woo JM, Lin Z, Navab M, Van Dyck C, Trejo‐Lopez Y, Woo KM, et al. Treatment with apolipoprotein A‐1 mimetic peptide reduces lupus‐like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010; 12: R93.; Black LL, Srivastava R, Schoeb TR, Moore RD, Barnes S, Kabarowski JH. Cholesterol‐independent suppression of lymphocyte activation, autoimmunity, and glomerulonephritis by apolipoprotein A‐I in normocholesterolemic lupus‐prone mice. J Immunol 2015; 195: 4685 – 98.; Schwendeman A, Sviridov DO, Yuan W, Guo Y, Morin EE, Yuan Y, et al. The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti‐inflammatory properties. J Lipid Res 2015; 56: 1727 – 37.; Urowitz MB, Gladman DD, Tom BD, Ibañez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152 – 8.; Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550 – 7.; Agarwal S, Elliott JR, Manzi S. Atherosclerosis risk factors in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 241 – 7.; Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: a population‐based cohort study. Lupus 2014; 23: 1546 – 52.; Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high‐density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012; 4: 251 – 68.; McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2428 – 37.; Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 83 – 91.; Srivastava R, Yu S, Parks BW, Black LL, Kabarowski JH. Autoimmune‐mediated reduction of high‐density lipoprotein–cholesterol and paraoxonase 1 activity in systemic lupus erythematosus–prone gld mice. Arthritis Rheum 2011; 63: 201 – 11.; Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS. Structure of HDL: particle subclasses and molecular components. Handb Exp Pharmacol 2015; 224: 3 – 51.; Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res 2013; 54: 2950 – 63.; Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392 – 410.; Matyus SP, Braun PJ, Wolak‐Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, et al. HDL particle number measured on the Vantera ®, the first clinical NMR analyzer. Clin Biochem 2015; 48: 148 – 55.; Lilleby V, Haugen M, Mørkrid L, Frøslie FK, Holven KB, Førre Ø. Body composition, lipid and lipoprotein levels in childhood‐onset systemic lupus erythematosus. Scand J Rheumatol 2007; 36: 40 – 7.; Soep JB, Mietus‐Snyder M, Malloy MJ, Witztum JL, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric‐onset systemic lupus erythematosus. Arthritis Rheum 2004; 51: 451 – 7.; Yuan J, Li LI, Wang Z, Song W, Zhang Z. Dyslipidemia in patients with systemic lupus erythematosus: association with disease activity and B‐type natriuretic peptide levels. Biomed Rep 2016; 4: 68 – 72.; Gaál K, Tarr T, Lőrincz H, Borbás V, Seres I, Harangi M, et al. High‐density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase‐1 activity in patients with systemic lupus erythematosus. Lipids Health Dis 2016; 15: 60.; Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 3947 – 57.; Gamal SM, Fawzy SM, Abdo M, Elgengehy FT, Ghoniem S, Alkemry A. Immunological profile and dyslipidemia in Egyptian systemic lupus erythematosus patients. Egypt Rheumatol 2017; 39: 89 – 92.; Heinecke JW. The not‐so‐simple HDL story: a new era for quantifying HDL and cardiovascular risk? Nat Med 2012; 18: 1346 – 7.; Chung CP, Oeser A, Raggi P, Solus JF, Avalos I, Linton MF, et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1227 – 33.; Wijaya LK, Kasjmir YI, Sukmana N, Subekti I, Prihartono J. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones 2005; 37: 132 – 44.; Kashef S, Ghaedian MM, Rajaee A, Ghaderi A. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti‐double‐stranded DNA (anti‐dsDNA) antibodies. Rheumatol Int 2007; 27: 235 – 41.; Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 2006; 54: 1283 – 90.; Cardoso CR, Signorelli FV, Papi JA, Salles GF. Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol Int 2008; 28: 323 – 7.; Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol 2016; 43: 745 – 50.; Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012; 64: 285 – 96.; Petri MA, Kiani AN, Post W, Christopher‐Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70: 760 – 5.; Hua X, Su J, Svenungsson E, Hurt‐Camejo E, Jensen‐Urstad K, Angelin B, et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease. Scand J Rheumatol 2009; 38: 184 – 9.; Juárez‐Rojas J, Medina‐Urrutia A, Posadas‐Sánchez R, Jorge‐Galarza E, Mendoza‐Pérez E, Caracas‐Portilla N, et al. High‐density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus 2008; 17: 981 – 7.; Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359 – 63.; Machado D, Sarni RO, Abad TT, Silva SG, Khazaal EJ, Hix S, et al. Lipid profile among girls with systemic lupus erythematosus. Rheumatol Int 2017; 37: 43 – 8.; Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus [review]. J Biomed Sci 2014; 21: 23.; Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, et al. Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest 2016; 126: 266 – 81.; Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti‐atherogenic and anti‐inflammatory properties of high‐density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 26 – 31.; Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz‐Zadeh J, Ravirajan C, et al. Antibodies to high‐density lipoprotein and β 2 ‐glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686 – 94.; Hb G, Rao VS, Kakkar VV. Friend turns foe: transformation of anti‐inflammatory HDL to proinflammatory HDL during acute‐phase response. Cholesterol 2011; 2011: 274629.; Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High‐density lipoprotein loses its anti‐inflammatory properties during acute influenza A infection. Circulation 2001; 103: 2283 – 8.; McMahon M, Grossman J, FitzGerald J, Dahlin‐Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541 – 9.; Smith CK, Vivekanandan‐Giri A, Tang C, Knight JS, Mathew A, Padilla RL, et al. Neutrophil extracellular trap–derived enzymes oxidize high‐density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol 2014; 66: 2532 – 44.; Heinecke JW. The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007; 9: 249 – 51.; Chan GK, Witkowski A, Gantz DL, Zhang TO, Zanni MT, Jayaraman S, et al. Myeloperoxidase‐mediated methionine oxidation promotes an amyloidogenic outcome for apolipoprotein A‐I. J Biol Chem 2015; 290: 10958 – 71.; Leffler J, Martin M, Gullstrand B, Tydén H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012; 188: 3522 – 31.; Carlucci PM, Purmalek MM, Dey AK, Temesgen‐Oyelakin Y, Sakhardande S, Joshi AA, et al. Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. JCI Insight 2018; 3: 99276.; Vivekanandan‐Giri A, Slocum JL, Byun J, Tang C, Sands RL, Gillespie BW, et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1725 – 31.; Szapacs ME, Kim HY, Porter NA, Liebler DC. Identification of proteins adducted by lipid peroxidation products in plasma and modifications of apolipoprotein A1 with a novel biotinylated phospholipid probe. J Proteome Res 2008; 7: 4237 – 46.; Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high‐density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis [review]. Arthritis Res Ther 2008; 10: 213.; Jiang X, Chen F. The effect of lipid peroxides and superoxide dismutase on systemic lupus erythematosus: a preliminary study. Clin Immunol Immunopathol 1992; 63: 39 – 44.; Artl A, Marsche G, Pussinen P, Knipping G, Sattler W, Malle E. Impaired capacity of acute‐phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH‐7 hepatoma cell line. Int J Biochem Cell Biol 2002; 34: 370 – 81.; Bergt C, Pennathur S, Fu X, Byun J, O’Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1‐dependent cholesterol transport. Proc Natl Acad Sci U S A 2004; 101: 13032 – 7.; Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, et al. Myeloperoxidase impairs ABCA1‐dependent cholesterol efflux through methionine oxidation and site‐specific tyrosine chlorination of apolipoprotein A‐I. J Biol Chem 2006; 281: 9001 – 4.; Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A‐I. Proc Natl Acad Sci U S A 2008; 105: 12224 – 9.; Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T. The versatility of HDL: a crucial anti‐inflammatory regulator. Eur J Clin Invest 2010; 40: 1131 – 43.; De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. High‐density lipoprotein mediates anti‐inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014; 15: 152 – 60.; Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF‐α‐induced vascular cell adhesion molecule‐1 expression. Int J Biochem Cell Biol 2003; 35: 168 – 82.; Smith CK, Seto NL, Vivekanandan‐Giri A, Yuan W, Playford MP, Manna Z, et al. Lupus high‐density lipoprotein induces proinflammatory responses in macrophages by binding lectin‐like oxidised low‐density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Ann Rheum Dis 2017; 76: 602 – 11.; Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro‐inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. Clin Immunol 2010; 137: 147 – 56.; Frostegård J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192 – 200.; Hansson GK, Libby P. The immune response in atherosclerosis: a double‐edged sword. Nat Rev Immunol 2006; 6: 508 – 19.; Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, et al. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006; 54: 1928 – 39.; Marsillach J, Becker JO, Vaisar T, Hahn BH, Brunzell JD, Furlong CE, et al. Paraoxonase‐3 is depleted from the high‐density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res 2015; 14: 2046 – 54.; Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998; 7: 355 – 60.; O’Neill SG, Giles I, Lambrianides A, Manson J, D’Cruz D, Schrieber L, et al. Antibodies to apolipoprotein A‐I, high‐density lipoprotein, and C‐reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62: 845 – 54.; Vuilleumier N, Reber G, James R, Burger D, de Moerloose P, Dayer JM, et al. Presence of autoantibodies to apolipoprotein A‐1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 353 – 60.; Townsend D, Hughes E, Hussain R, Siligardi G, Baldock S, Madine J, et al. Heparin and methionine oxidation promote the formation of apolipoprotein A‐I amyloid comprising α‐helical and β‐sheet structures. Biochemistry 2017; 56: 1632 – 44.

الإتاحة: https://doi.org/10.1002/art.41059Test
https://hdl.handle.net/2027.42/152788Test

المؤلفون: Kang, Jukyung, Kim, Sang Yeop, Vallejo, Daniel, Hageman, Tyler S., White, Derek R., Benet, Alexander, Coghlan, Jill, Sen, K. Ilker, Ford, Michael, Saveliev, Sergei, Tolbert, Thomas J., Weis, David D., Schwendeman, Steven P., Ruotolo, Brandon T., Schwendeman, Anna

المصدر: European Journal of Pharmaceutics and Biopharmaceutics ; volume 146, page 111-124 ; ISSN 0939-6411

مصطلحات موضوعية: Pharmaceutical Science, General Medicine, Biotechnology

الإتاحة: https://doi.org/10.1016/j.ejpb.2019.12.003Test
https://api.elsevier.com/content/article/PII:S0939641119313141?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0939641119313141?httpAccept=text/plainTest

المؤلفون: Kim, Sang Yeop, Yu, Minzhi, Morin, Emily E., Kang, Jukyung, Kaplan, Mariana J., Schwendeman, Anna

المساهمون: American Heart Association, National Institute of Arthritis and Musculoskeletal and Skin Diseases, MCubed, University of Michigan, National Institutes of Health, Lupus Research Institute

المصدر: Arthritis & Rheumatology ; volume 72, issue 1, page 20-30 ; ISSN 2326-5191 2326-5205

الإتاحة: https://doi.org/10.1002/art.41059Test